北 京 大 成 律 师 事 务 所 关 于 华 润 博 雅 生 物 制 药 集 团 股 份 有 限 公 司 2025 年 第 二 次 临 时 股 东 会 的 法 律 意 见 书 法律意见书——博雅生物 2025 年第二次临时股东会 北京大成律师事务所关于华润博雅生物制药集团股份有限 公司 2025 年第二次临时股东会的法律意见书 致：华润博雅生物制药集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范 性文件的要求，北京大成律师事务所（以下简称"本所"）接受华润博雅生物制 药集团股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2025 年 第二次临时股东会（以下简称"本次股东会"）。 本所声明：本所律师仅对本次股东会的召集程序、召开程序、出席会议人员 资格、召集人资格、表决程序、表决结果及会议决议发表法律意见，并不对本次 股东会所审议的议案、议案所涉及的数字及内容发表意见。本所律师同意将本法 律意见书随本次股东会其他信息披露 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东会决议事项的参与 度，本次股东会对中小投资者进行单独计票，中小投资者是指除上市公司董事、 监事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的其他 股东； 2、本次股东会不存在增加、变更、否决议案的情况； 3、本次股东会不存在变更前次股东会决议的情况； 证券代码：300294 证券简称：博雅生物 公告编号：2025-082 华润博雅生物制药集团股份有限公司 2025 年第二次临时股东会决议公告 （一）审议通过《关于修订<公司章程>及其附件的议案》 4、本次股东会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 华润博雅生物制药集团股份有限公司(以下简称公司)2025 年第二次临时股 东会通知已于 2025 年 10 月 28 日在中国证券监督管理委员会指定信息披露网站 巨潮资讯网（www.cninfo.com.cn）以公告方式发出。会议于 2025 年 11 月 13 日 在江西省抚州市高新技术产业开发区惠泉路 333 号公司会议室以 ...

证券代码：300294 证券简称：博雅生物 公告编号：2025-081 华润博雅生物制药集团股份有限公司 本次变更的项目合伙人、签字注册会计师为孙文举先生，2009 年取得中国 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于 2025 年 3 月 17 日召开了第八届董事会第九次会议，于 2025 年 4 月 10 日召开 2024 年年度股东 大会，审议通过了《关于 2025 年度续聘审计机构的议案》，同意续聘毕马威华 振会计师事务所（特殊普通合伙）（以下简称毕马威华振）为公司 2025 年度财 务审计及内部控制审计机构。具体内容详见公司于 2025 年 3 月 19 日在巨潮资讯 网（网址：http://www.cninfo.com.cn）上披露的《公司关于 2025 年度续聘审计机 构的公告》（公告编号：2025-013）。 近日，公司收到毕马威华振出具的《关于变更华润博雅生物制药集团股份有 限公司 2025 年度审计项目合伙人、签字注册会计师及质量控制复核人的函》， 现将相关变 ...

Group 1 - The core point of the article is that Boya Bio (SZ 300294) announced that as of the announcement date, Gaotejia Group has pledged approximately 37.32 million shares, accounting for 65.42% of its holdings [1] - As of the report, Boya Bio's market capitalization is 12.8 billion yuan [1] - For the first half of 2025, Boya Bio's revenue composition is as follows: blood products account for 84.58%, biochemical drugs account for 8.63%, pharmaceutical distribution accounts for 6.12%, other industries account for 0.65%, and other businesses account for 0.02% [1]

关于持股5%以上股东部分股份质押及解除司法冻结的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）近日收到 5%以上股 东深圳市高特佳投资集团有限公司（以下简称高特佳集团）出具的《关于部分股 份质押及解除司法冻结的告知函》，获悉高特佳集团将所持有公司的部分股份进 行质押及部分股份解除司法冻结，具体事项如下： 一、股东股份质押基本情况 （一）股东本次股份质押基本情况 2025 年 11 月 7 日，高特佳集团将其持有公司的无限售条件流通股 534,524 股（占公司总股本的 0.11%）质押给苏州诚河清洁设备有限公司进行融资，具体 情况如下： 证券代码：300294 证券简称：博雅生物 公告编号：2025-080 华润博雅生物制药集团股份有限公司 | | 是否为 | | | | | 是 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | | | 是否为 | 否 | | 质 | | 质 | | ...

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]

Group 1 - The company BoYa Bio (300294) reported that as of October 31, 2025, the number of shareholders on the consolidated credit account register is 30,801 [1]

Core Viewpoint - The report highlights the increasing accounts receivable among A-share pharmaceutical companies, with a significant number exceeding 10 billion yuan, indicating potential liquidity issues and financial health concerns in the industry [1][3]. Accounts Receivable Overview - As of the end of Q3, 14 A-share pharmaceutical companies reported accounts receivable exceeding 10 billion yuan, with Shanghai Pharmaceuticals leading at 88.783 billion yuan, followed by Jiuzhoutong at 39.09 billion yuan [3][4]. - The blood products sector has seen a notable increase in accounts receivable, with companies like Tiantan Biological and Boya Biological reporting significant year-on-year growth [5][6]. Industry Characteristics - The pharmaceutical distribution sector is primarily responsible for high accounts receivable, as public hospitals, which dominate the market, often negotiate longer payment terms, leading to increased receivables for distributors [3][10]. - Companies may adopt lenient credit policies to attract more clients, which can temporarily boost sales but also result in higher accounts receivable [3][10]. Financial Ratios - Eight companies have accounts receivable constituting over 50% of their total assets, with Renmin Tongtai having the highest ratio at 62.1% [8][9]. - *ST Suwu and Zhongyao Holdings follow, with accounts receivable ratios of 56.28% and significant increases compared to the previous year [9][10]. Performance Implications - High accounts receivable can lead to reduced cash flow and increased opportunity costs, potentially impacting profitability due to higher bad debt provisions [10]. - However, in certain scenarios, elevated accounts receivable may not be detrimental if they align with healthy revenue and profit growth, and if customer quality and payment terms are managed effectively [10].

Financial Performance - In the first three quarters of 2025, the company reported total revenue of CNY 1.473 billion, an increase of 18.38% year-on-year, while net profit attributable to shareholders decreased by 16.90% to CNY 342 million [2][3] - The decline in net profit is primarily due to inventory write-offs and asset depreciation resulting from the acquisition of Green Cross [2][3] Business Operations - The company continues to focus on blood products, successfully transferring 80% of its stake in Boya Xin to Fuzhou High-tech Zone Financial Investment Group in September [2][3] - Plasma collection reached 492 tons in the first nine months of 2025, a 5.2% increase compared to the same period last year, exceeding industry growth rates [3][5] Market Strategy - The company is adapting its marketing strategies in response to the results of the Guangdong Alliance procurement, which has seen stable pricing for blood products despite overall industry profit declines [3] - The management model for Green Cross includes three business centers to enhance integration and improve operational efficiency, leading to increased revenue and profit levels compared to pre-acquisition [3][4] Product Development - The company is promoting its 10% intravenous immunoglobulin (IVIG) product, with sales contingent on production schedules and regulatory approvals [3] - Factor products are experiencing rapid sales growth, supported by enhanced academic promotion and management strategies [3][4] Future Outlook - The company plans to expand its plasma collection stations, with a focus on new site approvals and operational efficiency to ensure growth above industry averages [6][9] - The internationalization strategy includes registering products in markets with favorable regulatory environments before targeting stricter markets like Europe and the US [8][9] - The company aims to enhance its product pipeline and optimize production processes to improve overall plasma utilization and revenue per ton of plasma [9]